ENETS 2021 | PALBONET trial: efficacy of palbociclib on G1 and G2 pNETs

Enrique Grande MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses the PALBONET trial (NCT02806648) and the efficacy of palbociclib, a CDK4 and CDK6 inhibitor, on patients with G1 and G2 pancreatic neuroendocrine tumors (pNET). Dr Grande also discusses how advancements in identification of biomarkers for pNETs is needed in the future to predict the activity of agents and ensure successful trials. This interview took place during the European Neuroendocrine Tumor Society (ENETS) 19th Annual Conference 2021.